We are live on ! Find out more
EVOK

Evoke Pharma
EVOK

Delisted

EVOK was delisted on the 16th of December, 2025.

Back to rankings

11 hedge funds and large institutions have $3.31M invested in Evoke Pharma in 2015 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 0 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

37% more capital invested

Capital invested by funds: $2.41M → $3.31M (+$899K)

0.94% more ownership

Funds ownership: 6.59% → 7.53% (+0.94%)

0% more funds holding

Funds holding: 11 → 11 (0)

0% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 2

Holders
11
Holders Change
–
Holders Change %
0%
% of All Funds
0.29%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
3
Reduced
–
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
KCM
Knoll Capital Management
Florida
+$337K
2
OM
Opaleye Management
Massachusetts
+$30.7K
3
FANJ
Financial Architects (New Jersey)
New Jersey
+$27.1K
4
Bank of America
Bank of America
North Carolina
+$18K
5
Vanguard Group
Vanguard Group
Pennsylvania
+$17.1K

Top Sellers

Rank Fund Capital Flow
1
Deutsche Bank
Deutsche Bank
Germany
-$2K
2
UBS Group
UBS Group
Switzerland
-$2K

EVOK Hedge Fund Activity: Q1 2015 in Review

11 of the 3,770 institutional investors tracked by Wall St. Rank reported a position in Evoke Pharma (EVOK) for Q1 2015, worth a combined $3.31M — up 37% from $2.41M a quarter earlier.

Fund positioning in EVOK was balanced in Q1 2015: 2 funds opened new positions, 2 closed out, 3 added to existing stakes and 0 trimmed.

The largest buyer was Knoll Capital Management, opening a new position worth an estimated $337K. The largest seller was Deutsche Bank, exiting entirely with an estimated $2K sold.

  • 11 institutional investors held Evoke Pharma (EVOK) as of Q1 2015, unchanged from Q4 2014.
  • Funds reported $3.31M of Evoke Pharma stock for Q1 2015, up 37% quarter-over-quarter.
  • 2 funds opened new Evoke Pharma positions in Q1 2015 and 2 closed out, a net change of 0 holders.
  • The largest Evoke Pharma buyer in Q1 2015 was Knoll Capital Management, an estimated $337K added.
  • The largest Evoke Pharma seller in Q1 2015 was Deutsche Bank, an estimated $2K sold.

Based on aggregated 13F filings for Q1 2015.